Virtual Symposium: Lipid Management in Very High-Risk Patients Post-MI: Applying Real-World Evidence to Improve Outcome

Patients with a recent myocardial infarction (MI) are classified as very high-risk for future atherosclerotic cardiovascular disease (ASCVD) events according to current guidelines, however, targeted LDL-C achievement and optimization of lipid lowering therapy (LLT) in these patients remains suboptimal. For example, recent numbers from the GOULD registry, have shown that <40% of patients with a prior MI were on optimal LLT at enrollment, and only 13.2% had lipid therapy intensified.

In turn, these gaps perpetuate the risk of future adverse events that patients with a recent MI will experience. Despite the intensive medical management following an MI, risk of a recurrent CV event is substantial and patients with a recent MI have significant loss of productivity the year after the event. Furthermore, this burden is more pronounced in very high-risk patients, including those with a high burden of cardiometabolic comorbidities, compared to patients who are not very-high risk. During this enduring symposium, experts will provide guidance on the clinical application of statin and nonstatin therapies in this setting, as well as information about new and emerging studies that can further inform patient selection in order to optimize outcomes.

This activity is part of the Lipid Management Digital Hub.

Target Audience

This activity is designed for US-based healthcare professionals, including primary care clinicians (PCPs), nurse practitioners (NPs), physician assistants (PAs), endocrinologists, diabetologists, pharmacists, cardiologists, lipidologists, dieticians, registered nurses, and other allied health professionals.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Review current guideline recommendations for lipid testing, lipid targets, and lipid-lowering therapy in patients with a recent MI
  • Interpret the efficacy and safety of PCSK9 inhibitors from clinical trials and RWE studies in ACS patients and their implications for patient selection
  • Develop individualized treatment strategies for very-high risk ASCVD patients with a recent MI that prioritize the early initiation and intensification of treatment to optimize overall outcomes
Course summary
Available credit: 
  • 1.25 ACPE Pharmacy
  • 1.25 AMA PRA Category 1 Credit
  • 1.25 ANCC
  • 1.25 CDE
  • 1.25 Participation
Course opens: 
Course expires: 


Pam Taub, MD (Chair)
Associate Professor of Medicine
Director of Step Family Foundation Cardiovascular
Rehabilitation and Wellness Center
UC San Diego Health System
Division of Cardiovascular Medicine
La Jolla, CA

Dr. Taub discloses the following:
Salary: UC San Diego
Consulting Fees: Amgen, Sanofi/Regeneron, Novo-nordisk, Esperion Therapeutics, Boehringer-Ingelheim
Contracted Research: Grant: Federal Emergency Management Agency, National Institutes of Health, American Heart Association…..Research Support: Applied Therapeutics
Ownership Interest less than 5% (stocks, stock options, or other ownership interest excluding diversified mutual funds): Epirium Bio: Stock/Shareholder



Nihar R. Desai, MD
Associate Professor of Medicine
Yale School of Medicine
New Haven, CT

Dr. Desai discloses the following:
Consulting Fees: Amgen, Boehringer Ingelheim, Cytolytics, Novartis, Relypsa, SC Pharma
Contracted Research: Amgen, Boehringer Ingelheim, Cytolytics, AstraZeneca, Novartis



Michael D. Shapiro, DO
Fred M. Parrish Professor of Cardiology and Molecular Medicine
Director, Center for Prevention of Cardiovascular Disease
Section on Cardiovascular Disease
Wake Forest Baptist Health
Wake Forest, NC

Dr. Shapiro discloses the following:
Consulting Fees: Alexion, Amgen, Esperion, Novartis
Contracted Research: NHLBI, Novartis, Amgen

1.25 hours

This activity is supported by educational funding from Amgen.


In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.25 contact hours. 

Postgraduate Institute for Medicine designates this continuing education activity for 1.25 contact hour(s) (.125 CEUs) of the Accreditation Council for Pharmacy Education.

This is an application-based activity. Universal Activity Numbers (UAN): JA4008162-9999-21-406-H01-P

For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.

This program offers 1.25 CPEUs for dieticians.


Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine's (ABIM) maintenance of certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The PIM planners and others have nothing to disclose. The CMHC planners and others have nothing to disclose.

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.  The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management.  Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

During the period September 10, 2021 through September 10, 2022, participants must read the learning objectives and faculty disclosures, study the educational activity, obtain a score of 75% or better on the post-test, and complete the evaluation. Upon completing, your certificate will be available for print. For questions about receiving certificates, please contact us at

For questions about the accreditation of this activity, please visit

For Pharmacists: Please complete the evaluation instructions above. Upon registering and completing the activity evaluation, your transcript information will be sent to the NABP CPE Monitor Service within 4-6 weeks.

Available Credit

  • 1.25 ACPE Pharmacy
  • 1.25 AMA PRA Category 1 Credit
  • 1.25 ANCC
  • 1.25 CDE
  • 1.25 Participation
Please login or register to take this course.

Required Hardware/software

A computer with an internet connection

Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser

Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.